The Pirbright Institute, Pirbright, United Kingdom; The Royal Veterinary College (VEEPH), University of London, United Kingdom.
The Şap Institute, Ankara, Turkey.
Vaccine. 2014 Apr 1;32(16):1848-55. doi: 10.1016/j.vaccine.2014.01.071. Epub 2014 Feb 11.
Foot-and-mouth disease (FMD) is present in much of Turkey and its control is largely based on vaccination. The arrival of the FMD Asia-1 serotype in Turkey in 2011 caused particular concern, spreading rapidly westwards across the country towards the FMD free European Union. With no prior natural immunity, control of spread would rely heavily on vaccination. Unlike human vaccines, field protection is rarely evaluated directly for FMD vaccines. Between September 2011 and July 2012 we performed four retrospective outbreak investigations to assess the vaccine effectiveness (VE) of FMD Asia-1 vaccines in Turkey. Vaccine effectiveness is defined as the reduction in risk in vaccinated compared to unvaccinated individuals with similar virus exposure in the field. The four investigations included 12 villages and 1230 cattle >4 months of age. One investigation assessed the FMD Asia-1 Shamir vaccine, the other three evaluated the recently introduced FMD Asia-1 TUR 11 vaccine made using a field isolate of the FMD Asia-1 Sindh-08 lineage that had recently entered Turkey. After adjustment for confounding, the TUR 11 vaccine provided moderate protection against both clinical disease VE=69% [95% CI: 50%-81%] and infection VE=63% [95% CI: 29%-81%]. However, protection was variable with some herds with high vaccine coverage still experiencing high disease incidence. Some of this variability will be the result of the variation in virus challenge and immunity that occurs under field conditions. In the outbreak investigated there was no evidence that the Asia-1 Shamir vaccine provided adequate protection against clinical FMD with an incidence of 89% in single vaccinated cattle and 69% in those vaccinated two to five times. Based on these effectiveness estimates, vaccination alone is unlikely to produce the high levels of herd immunity needed to control FMD without additional control measures.
口蹄疫(FMD)在土耳其的大部分地区都存在,其控制主要依赖于疫苗接种。2011 年,FMD 亚洲-1 血清型在土耳其的出现引起了特别关注,该病毒迅速向西传播,蔓延至该国无 FMD 的欧盟地区。由于没有先前的自然免疫力,传播的控制将严重依赖于疫苗接种。与人类疫苗不同,很少直接评估口蹄疫疫苗的现场保护效果。2011 年 9 月至 2012 年 7 月,我们进行了四项回顾性暴发调查,以评估 FMD 亚洲-1 疫苗在土耳其的疫苗有效性(VE)。疫苗有效性定义为在野外具有相似病毒暴露风险的情况下,接种疫苗与未接种疫苗的个体相比,风险降低的程度。这四项调查包括 12 个村庄和 1230 头 4 个月以上的牛。一项调查评估了 FMD 亚洲-1 Shamir 疫苗,另外三项评估了最近引入的 FMD 亚洲-1 TUR 11 疫苗,该疫苗使用了最近进入土耳其的 FMD 亚洲-1 Sindh-08 谱系的田间分离株。在调整混杂因素后,TUR 11 疫苗对临床疾病的保护效果适中,VE=69%[95%CI:50%-81%],对感染的保护效果 VE=63%[95%CI:29%-81%]。然而,保护效果存在差异,一些高疫苗覆盖率的牛群仍经历高疾病发病率。这种差异的部分原因是在野外条件下病毒挑战和免疫的变化。在调查的暴发中,没有证据表明 Asia-1 Shamir 疫苗对口蹄疫临床病例提供充分的保护,单接种疫苗的牛的发病率为 89%,接种 2 至 5 次的牛的发病率为 69%。根据这些有效性估计,如果不采取额外的控制措施,仅依靠疫苗接种不太可能产生控制口蹄疫所需的高水平群体免疫力。